Triptolide-Containing Formulation for Autosomal Dominant Polycystic Kidney Disease
Autosomal Dominant Polycystic Kidney Disease
Enrolment: 100 · Results not recorded
Loading the evidence…
Drug
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
Autosomal Dominant Polycystic Kidney Disease
Enrolment: 100 · Results not recorded
AIDS/HIV
Enrolment: 18 · Results not recorded
HIV-infection/AIDS
Enrolment: 353 · Results not recorded
Crohn's Disease
Enrolment: 40 · Results not recorded
Adenosquamous Carcinoma of the Pancreas
Enrolment: 16 · Results not recorded
HIV
Enrolment: 150 · Results not recorded
Advanced Lung Non-Small Cell Carcinoma
Enrolment: 8 · Results not recorded
Advanced Cancer · Pancreatic Cancer
Enrolment: 66 · Results not recorded
Polycystic Kidney
Enrolment: 300 · Results not recorded
HIV
Enrolment: 23 · Results not recorded
1 studies reported at therapy level; 1 evidence entries itemised.
Model: Middle cerebral artery occlusion for 2 h using an intraluminal silicone-tipped filament, followed by 24 h reperfusion
Vehicle-treated rats had an infarct volume of 21 per cent (SD 3) and brain water content of 83 per cent (SD 2). Triptolide dose-dependently reduced infarct volume and brain water content (p less than 0.05) and improved neurological deficit scores at 0.5 and 5 mg/kg, while reducing pro-inflammatory…
Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.92. Machine-extracted fields require source verification.